2nd Quarter - Report

BROWNSTEIN HYATT FARBER SCHRECK, LLP for NOVARTIS

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medical/Disease Research/Clinical Labs MED

Issues related to cell and gene therapy Pharmaceutical pricing Issues related to the development of therapies for rare diseases H.R. 748 CARES Act, Issues related to COVID-19 treatment

LobbyistCovered position, as disclosed
EMILY FELDER —

Contacted: Office of the Vice President of the United States; SENATE; HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Natl Economic Council (NEC)

Bills named: H.R. 748 (116th)

Health Issues HCR

Issues related to cell and gene therapy Pharmaceutical pricing Issues related to the development of therapies for rare diseases H.R. 748 CARES Act, Issues related to COVID-19 treatment

LobbyistCovered position, as disclosed
NADEAM ELSHAMI —
MARC LAMPKIN —
BRIAN MCKEON —
RADHA MOHAN —
JEROME MURRAY —
ZACHARY PFISTER —
BRIAN WILD —

Contacted: Natl Economic Council (NEC); Executive Office of the President (EOP); SENATE; Office of the Vice President of the United States; HOUSE OF REPRESENTATIVES

Bills named: H.R. 748 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.